title: Systemic pharmacokinetics of rifaximin in volunteers with shigellosis.
abstract: Rifaximin is an oral antibiotic indicated for treatment of traveler's diarrhea. Rifaximin pharmacokinetics were evaluated in individuals challenged with Shigella flexneri. Peak plasma rifaximin concentrations were low after nine consecutive doses, and no accumulation was observed. Rifaximin serum levels were minimal and similar to those previously reported in studies of healthy volunteers.
authors: Center for Immunization Research, Department of International Health, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. david.taylor@vaxinnate.com
authors: David N
authors: DN
authors: Taylor
authors: Robin
authors: R
authors: McKenzie
authors: Anna
authors: A
authors: Durbin
authors: Colleen
authors: C
authors: Carpenter
authors: Robert
authors: R
authors: Haake
authors: A Louis
authors: AL
authors: Bourgeois
mesh_terms: D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004405:Dysentery, Bacillary / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012294:Rifamycins / Q000008:administration & dosage / Q000493:pharmacokinetics*; D000078262:Rifaximin; D012763:Shigella flexneri / Q000187:drug effects* / Q000472:pathogenicity; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D012294:Rifamycins; D000078262:Rifaximin